TY - JOUR
T1 - Matrix metalloproteinase-12 as an endogenous resolution promoting factor following myocardial infarction
AU - Mouton, Alan J.
AU - Rivera Gonzalez, Osvaldo J.
AU - Kaminski, Amanda R.
AU - Moore, Edwin T.
AU - Lindsey, Merry L.
N1 - Funding Information:
We acknowledge funding from the American Heart Association18POST34000039, National Institutes of Health under Award Numbers GM104357, GM114833, GM115428, HL051971, HL075360, HL105324, and HL129823, and from the Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development under Award Number 5I01BX000505. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association, the National Institutes of Health, or the Veterans Administration.
Funding Information:
We acknowledge funding from the American Heart Association 18POST34000039 , National Institutes of Health under Award Numbers GM104357, GM114833, GM115428, HL051971, HL075360, HL105324, and HL129823, and from the Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development under Award Number 5I01BX000505. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association, the National Institutes of Health, or the Veterans Administration.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/11
Y1 - 2018/11
N2 - Following myocardial infarction (MI), timely resolution of inflammation promotes wound healing and scar formation while limiting excessive tissue damage. Resolution promoting factors (RPFs) are agents that blunt leukocyte trafficking and inflammation, promote necrotic and apoptotic cell clearance, and stimulate scar formation. Previously identified RPFs include mediators derived from lipids (resolvins, lipoxins, protectins, and maresins), proteins (glucocorticoids, annexin A1, galectin 1, and melanocortins), or gases (CO, H 2 S, and NO). Matrix metalloproteinase-12 (MMP-12; macrophage elastase) has shown promising RPF qualities in a variety of disease states. We review here the evidence that MMP-12 may serve as a novel RPF with potential therapeutic efficacy in the setting of MI.
AB - Following myocardial infarction (MI), timely resolution of inflammation promotes wound healing and scar formation while limiting excessive tissue damage. Resolution promoting factors (RPFs) are agents that blunt leukocyte trafficking and inflammation, promote necrotic and apoptotic cell clearance, and stimulate scar formation. Previously identified RPFs include mediators derived from lipids (resolvins, lipoxins, protectins, and maresins), proteins (glucocorticoids, annexin A1, galectin 1, and melanocortins), or gases (CO, H 2 S, and NO). Matrix metalloproteinase-12 (MMP-12; macrophage elastase) has shown promising RPF qualities in a variety of disease states. We review here the evidence that MMP-12 may serve as a novel RPF with potential therapeutic efficacy in the setting of MI.
KW - Extracellular matrix
KW - Fibroblast
KW - Inflammation
KW - Inflammation resolution
KW - Macrophage
KW - Neutrophil
UR - http://www.scopus.com/inward/record.url?scp=85055735258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055735258&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2018.10.026
DO - 10.1016/j.phrs.2018.10.026
M3 - Review article
C2 - 30394317
AN - SCOPUS:85055735258
VL - 137
SP - 252
EP - 258
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
ER -